Bayer successful In Approving Its Adempas From FDA

A German Drug manufacturer Bayer AG has approving its drugs designed for two types of pulmonary hypertension from the U.S. Food and Drug Administration.

According to statement made by US regulator on Tuesday, two of the drugs of German manufacture  i.e. the Adempas, with a second name riociguat, is approved for the treatment of a uncommon disease normally origin by blood clots that hamper the course of blood between heart and lungs, a disease commonly known as thromboembolic pulmonary hypertension.

As well as the drug is also used for the condition when arteries of the lungs tighten, pushing the heart to work harder, resulting in a condition in which fatigue,  shortness of breath, potential heart failure and weakness occur, while the medical name of condition is pulmonary arterial hypertension.

But the drugs carry a serious warning that it would be harmful for those women who are pregnant women because it can be harmful for the fetus. All women who have this disease must fulfill with pregnancy testing be enrolled in a risk easing program, and be advise on the necessity for contraception.

Doctors who recommend the drugs to the patients should be well versed with the program of drug or obligatory to be qualified by join up in the program, and the drug retailers will only be capable to distribute Adempas to patients entitled to get it under the risk easing program.

The drug Adempas belongs to a group of medicine that is recognized as soluble guanylate cyclase stimulators. These types of drugs aid arteries to relax after it boost the blood flow in arteries and lowered the blood pressure, as well as this formula is also useful in improving the capability of patients to exercise.

Initially it was recommended by FDA that the drug be approved for a doses less than the2.5 mg dose anticipated by the drug manufacture, because the firm believe initiating dose of 0.5 milligram and upper limit dose of 1.5 milligrams thrice a day would present the same advantage as the upper quantity with a decrease the risk of side effects, mainly in low blood pressure patient.